UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): January 30, 2020

Corteva, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or other jurisdiction of Incorporation)

001-38710 (Commission File Number)

974 Centre Road, Building 735 Wilmington, Delaware 19805

Name of each exchange on which

82-4979096

(I.R.S. Employer

Identification No.)

(Address of principal executive offices)(Zip Code)

(302) 485-3000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	registered
Common Stock, par value \$0.01 per share	CTVA	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company $\ \square$

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition

On January 30, 2020, Corteva, Inc. (the "Company") announced its consolidated financial results for the quarter and year ended December 31, 2019. A copy of the Company's press release, financial statement schedules, and related presentation are furnished herewith on Form 8-K as Exhibits 99.1, 99.2, and 99.3, respectively. The information contained in this report, including Exhibits 99.1, 99.2, and 99.3, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section. In addition, the information contained in this report shall not be deemed to be incorporated by reference into any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

 99.1
 Press Release dated January 30, 2020

 99.2
 Financial Statement Schedules dated January 30, 2020

 99.3
 Corteva Fourth Quarter 2019 Earnings Presentation dated January 30, 2020

 104
 The cover page from the Company's Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORTEVA, INC. (Registrant)

/s/ Brian Titus

Brian Titus Vice President and Controller

January 30, 2020



Corteva Reports Fourth Quarter and Full Year 2019 **Results and Provides 2020 Guidance**

WILMINGTON, Del., Jan. 30, 2020 - Corteva, Inc. (NYSE: CTVA) today reported financial results for the quarter ended December 31, 2019 and the full year 2019. The Company also provided 2020 guidance.

	Net Sales	EPS	Income from Cont. Ops. (After Tax)
GAAP	\$13.8 B	\$0.02	\$26 M
vs. FY 2018 ²	(3)%	+100% ⁶	+101% ⁶
	Organic Sales ¹	Operating EPS ¹	Operating EBITDA
NON-GAAP	\$14.3 B	\$1.43	\$2.0 B
vs. FY 2018 ²	- %	(6)%	(4)%

- Full year reported net sales for 2019 were \$13.8 billion, Operating EBITDA¹ was \$2.0 billion, down 4% down 3% versus the prior year, driven by currency.
- GAAP earnings per share (EPS) from continuing operations were \$0.02 for the full year - and GAAP income from continuing operations after taxes was \$26 million
- Outside of North America,3 net sales in 2019 grew 1%, with an increase of 1% in Crop Protection and flat Seed sales. New product sales led to Rest of World organic sales¹ growth of 7% in Crop Protection and 6% in Seed
- versus prior year, as weather-related declines in North America and currency impacts were partially offset by cost savings, gain on divestitures, and contribution from new products.
- Merger cost synergies were approximately \$350 million for 2019, on track to deliver \$1.2 billion by 2021.
- Corteva returned approximately \$220 million to shareholders in 2019, in line with previous commitments.



"Our results show that we capitalized on the strength of our product pipeline to realize abovemarket organic growth especially outside of North America. We also delivered on our costsynergy commitments and intensified our productivity actions. In our first six months as a stand-alone company, we demonstrated our collective strengths and our ability to navigate unprecedented market conditions to finish strong."

"As we look forward, we expect more normal weather conditions in North America will set the stage for further performance improvements. We remain committed to driving shareholder value and financial results consistent with our stated priorities."

- James C. Collins, Jr., Corteva Chief Executive Officer

Enlist E3[™] Soybean Launch Accelerated

Company Updates



Corteva is accelerating the ramp-up of its Enlist E3^{™4} soybeans, as well as its Enlist One® and Enlist Duo® herbicides, in the U.S. and Canada. Solid commercial and research performance results for the system in 2019 support acceleration. More than 20 additional licensees have been

signed in the fourth quarter for a total of 120 licensees.

Conkesta Insect Control Trait **Receives China Approval**

Corteva received import authorization from China for the Conkesta[™] soybean insect control trait in the fourth quarter. The trait approval had been in progress in China since 2014. The receipt of China import approval is a necessary step for commercialization of Conkesta E3[™] in Latin America, which is on track for the early 2020s.

Crop Protection Asset Sales Demonstrate Best-Owner Model

Corteva agreed to sell Chlorpyrifos assets in India: Bensulfuron-Methyl assets in Asia Pacific (excluding China); Quinoxyfen business assets; and a selection of U.S. herbicide brands during the fourth quarter. These actions are aligned with the Company's commitment to driving an active portfolio management approach focused on margin expansion and shareholder value creation.

rating EPS, Pro Forma Operating EPS, Operating EBITDA and Pro Forma Operating EBITDA are non-GAAP measures. See page 6 for further discussion. 2. First Quarter 2019 and prior year GA and was determined in accordance with Artide 11 of Regulation S-X. Non-GAAP measures for these periods are reconciled to the GAAP prof. Age for a set as a set of the set



News Release 4Q & FY 2019

	Net Sales	EPS	Loss from Cont. Ops. (After Tax)
GAAP	\$3.0 B	\$(0.06)	\$(42) M
vs. 4Q 2018 ²	+6%	+94%	+94%
	Organic Sales ¹	Operating EPS ¹	Operating EBITDA ¹
NON-GAAP	\$3.1 B	\$0.07	\$224 M
vs. 4Q 2018 ²	9%	+170%	+348%

Summary of Fourth Quarter 2019

For the fourth quarter ended December 31, 2019, reported net sales increased 6% versus the same period last year, with organic sales¹ increases of 9%.

Volumes increased 6% versus the prior-year period. Volume gains in both segments were driven primarily by North America as a result of stronger sales in multichannel seed brands; penetration of EnlistTM herbicides in preparation for the 2020 planting season; and sales of new products in Latin America and EMEA³.

Local price increased 3% versus the prior-year period, with higher prices in Latin America due to favorable mix from PowerCore Ultra® sales. Currency was a headwind of 3%, primarily from the Brazilian Real.

The Company achieved approximately \$50 million in merger-related synergies in the quarter.

GAAP loss from continuing operations after income taxes was \$(42) million for the fourth quarter. Operating EBITDA¹ was \$224 million, a \$174 million improvement versus the same period last year on a pro forma basis².

Crop Protection operating EBITDA improvement reflects merger-related cost synergies, gains on divestitures, and higher sales. Seed Operating EBITDA improvement reflects pricing gains resulting from favorable mix, merger-related cost synergies and continued productivity.

The Company reported a loss of (0.06) for GAAP EPS from continuing operations and operating EPS¹ of 0.07 for the fourth quarter 2019.

(\$ in millions, except where noted)	FY 2019	FY 2018	% Change	% Organic Change
Net Sales	\$13,846	\$14,287	(3)%	- %
North America	\$6,929	\$7,412	(7)%	(6)%
EMEA	\$2,740	\$2,765	(1)%	7%
Latin America	\$2,889	\$2,817	3%	8%
Asia Pacific	\$1,288	\$1,293	- %	3%

(\$ in millions, except where noted)	4Q 2019	4Q 2018	% Change	% Organic Change ¹
Net Sales	\$2,983	\$2,815	6%	9%
North America	\$1,129	\$978	15%	16%
EMEA	\$404	\$386	5%	7%
Latin America	\$1,109	\$1,083	2%	8%
Asia Pacific	\$341	\$368	(7)%	(6)%



Crop Protection Summary

Crop Protection net sales were \$6.3 billion in 2019, down from \$6.4 billion in 2018. The decrease was due to a 3% decline in currency and a 1% impact from portfolio, partially offset by a 1% increase in volume. Local price was flat.

Unfavorable currency impacts were primarily due to the Brazilian Real and the Euro. Volume gains driven by new product launches – including Enlist[™] and Arylex[™] herbicides, as well as Isoclast[™] insecticide – were partially offset by unfavorable weather in North America, which resulted in lost spring applications. Pricing gains from new product launches were offset by increased grower incentive program discounts in North America. The portfolio impact was driven by divestitures in North America and Asia Pacific.

Despite sales declines in 2019, Crop Protection pro forma operating EBITDA was \$1.1 billion in 2019, essentially flat with 2018. Volume declines in North America, the unfavorable impact of currency and higher input costs more than offset cost synergies, sales from new products and ongoing productivity.

(\$ in millions, except where noted)	FY 2019	FY 2018	% Change	% Organic Change ¹		
North America	\$2,205	\$2,438	(10)%	(9)%		
EMEA	\$1,362	\$1,357	- %	7%		
Latin America	\$1,759	\$1,715	3%	8%		
Asia Pacific	\$930	\$935	(1)%	3%		
Total FY Crop Protection Net Sales			(3)%	1%		

Crop protection net sales for the fourth quarter of 2019 were \$1.7 billion, up 3% versus the prior-year period. The increase was due to an 8% increase in volume, which was partially offset by a 3% decline in currency, 1% decline in local price and 1% impact from portfolio.

Volume gains were primarily driven by new product launches, including Enlist[™] herbicide, coupled with a strong demand for insecticides in Latin America. Unfavorable currency impacts were primarily due to the Brazilian Real. Pricing gains from new product launches were more than offset by increased grower incentive program discounts in North America. The portfolio impact was driven by divestitures in North America and Asia Pacific.

Crop Protection operating EBITDA was \$277 million in the fourth quarter, up from \$169 million in the same quarter last year. Cost synergies, gains on divestitures, and volume gains more than offset increased selling costs and the impact of portfolio changes.

(\$ in millions, except where noted)	4Q 2019			% Organic Change ¹
North America	\$643	\$594	8%	9%
EMEA	\$226	\$200	\$200 13%	
Latin America	\$615	\$613	- %	7%
Asia Pacific	\$256	\$282	(9)%	(7)%
Total 4Q Crop Protection Net Sales	\$1,740	\$1,689	3%	7%



Seed Summary

Seed net sales were approximately \$7.6 billion in 2019, down from \$7.8 billion in 2018. The decrease was due to a 2% decline in currency and a 1% decline in volume. Local price was flat.

Unfavorable currency impacts were primarily due to the Brazilian Real, Eastern European currencies, and the Euro. Volume gains in corn in EMEA were more than offset by significant weather-related planting delays in North America, leading to a reduction in planted area for soybeans, and multi-channel and multi-brand rationalization impacts in North America. Competitive pricing pressure in soybeans in the U.S. and increased soybean and corn replant in North America were offset by favorable mix and continued penetration of PowerCore Ultra® in Latin America.

Seed pro forma operating EBITDA was \$1.0 billion in 2019, down 9% vs. the prior year. Competitive pricing pressure, the unfavorable impact of currency, increased commissions and input costs, and volume declines more than offset cost synergies and ongoing productivity.

(\$ in millions, except where noted)	FY 2019	FY 2018	% Change	% Organic Change ¹
North America	\$4,724	\$4,974	(5)%	(5)%
EMEA	\$1,378	\$1,408	\$1,408 (2)%	
Latin America	\$1,130	\$1,102	3%	7%
Asia Pacific	\$358	\$358	- %	4%
Total FY Seed Net Sales	\$7,590	\$7,842 (3)%		(1)%

Seed net sales were 1.2 billion in the fourth quarter of 2019, up from 1.1 billion in the same quarter last year. The increase was due to an 8% increase in local price and a 5% increase in volume, partially offset by a 3% decline in currency.

The increase in local price was primarily driven by favorable mix in Latin America from PowerCore Ultra® and in North America due to pricing gains in corn and licensing incomes. Volume gains were driven by increased deliveries of multi-channel brands in North America.

Unfavorable currency impacts were largely driven by the Brazilian Real.

Seed operating EBITDA was a seasonal loss of \$(26) million for the fourth quarter of 2019, as compared to a loss of \$(87) million in the same quarter last year. Pricing gains on favorable mix and cost synergies and ongoing productivity were partially offset by higher input costs driven by higher royalties and lower production yields.

(\$ in millions, except where noted)	4Q 2019	4Q % 2018 Change		% Organic Change ¹		
North America	\$486	\$384	27%	26%		
EMEA	\$178	\$186 (4)%		(3)%		
Latin America	\$494	\$470	5%	11%		
Asia Pacific	\$85	\$86	(1)%	(4)%		
Total 4Q Seed Net Sales	\$1,243	\$1,126	10%	13%		



Outlook

The Company provided guidance⁵ for full year 2020 net sales of approximately \$14.5 billion and expects operating EBITDA of approximately \$2.2 billion for the same period. The Company's operating EPS range is expected to be between \$1.45 and \$1.55 per share.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of its control, such as significant items, without unreasonable effort.

Fourth Quarter Conference Call

The Company will host a <u>live webcast</u> of its fourth quarter and full-year earnings conference call with investors to discuss its results and outlook today, January 30, 2020, at 9:00 a.m. ET. The slide presentation that accompanies the conference call is posted on the Company's Investor Events and Presentations page. A replay of the webcast will also be available on the <u>Investor Events and Presentations page</u>.

About Corteva Agriscience

Corteva, Inc. (NYSE: CTVA) is a publicly traded, global pure-play agriculture company that provides farmers around the world with the most complete portfolio in the industry – including a balanced and diverse mix of seed, crop protection and digital solutions focused on maximizing productivity to enhance yield and profitability. With some of the most recognized brands in agriculture and an industry-leading product and technology pipeline well positioned to drive growth, the Company is committed to working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. Corteva became an independent public company on June 1, 2019, and was previously the Agriculture Division of DowDuPont. More information can be found at www.corteva.com.

Follow Corteva on Facebook, Instagram, LinkedIn, Twitter and YouTube.

Cautionary Statement About Forward-Looking Statements

This communication contains estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "guidance", "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates" or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's strategy for growth, product development, regulatory approval, market position, anticipated benefits of recent acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures, and financial results, as well as expected benefits from, the separation of Corteva from DuPont, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in our forwardlooking statements and other estimates could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva's business, results of operations and financial condition. Some of the important factors that could cause Corteva's actual results to differ materially from those projected in any such forward-looking statements or estimates include: (i) effect of competition and consolidation in Corteva's industry; (ii) failure to successfully develop and commercialize Corteva's pipeline; (iii) failure to obtain or maintain the necessary regulatory approvals for some Corteva's products; (iv) failure to enforce Corteva's intellectual property rights or defend against intellectual property claims asserted by others; (v) effect of competition from manufacturers of generic products; (vi) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (vii) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (viii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products; (ix) effect of changes in agricultural and related policies of governments and international organizations; (x) effect of disruptions to Corteva's supply chain, information technology or network systems; (xi) competitor's establishment of an intermediary platform for distribution of Corteva's products; (xii) effect of volatility in Corteva's input costs; (xiii) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xiv) failure of Corteva's customers to pay their debts to Corteva, including customer financing programs; (xv) failure to realize the anticipated benefits of the internal reorganizations taken by DowDuPont in connection with the spin-off of Corteva; (xvi) failure to benefit from significant cost synergies and risks related to the indemnification obligations of legacy DuPont liabilities in connection with the separation of Corteva; (xvii) increases in pension and other post-employment benefit plan funding obligations; (xviii) effect of compliance with environmental laws and requirements and adverse judgments on litigation; (xix) risks related to Corteva's global operations; (xx) effect of climate change and unpredictable seasonal and weather factors; (xxi) effect of counterfeit products; (xxii) failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions; and (xxiii) risks related to our estimates with respect to goodwill and intangible assets.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expressed of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement or other estimate, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements and estimates is included in the "Risk Factors" section of Exhibit 99.1 of Amendment No. 4 to Corteva's Registration Statement on Form 10 and of



Corteva's Quarterly Report on Form 10-Q for the period ended September 30, 2019, as modified by subsequent reports on Form 10-Q, 10-K and Current Reports on Form 8-K.

Corteva Unaudited Pro Forma Financial Information

In order to provide the most meaningful comparison of results of operations, supplemental unaudited pro forma financial information for the first quarter of 2019 and prior has been included in this presentation. This presentation presents the pro forma results of Corteva, after giving effect to events that are (1) directly attributable to the merger of DuPont and Dow, debt retirement transactions related to paying off or retiring portions of Historical DuPont's existing debt liabilities, and the separation and distribution to DowDuPont stockholders of all the outstanding shares of Corteva common stock; (2) factually supportable and (3) with respect to the pro forma statements of income, expected to have a continuing impact on the consolidated results. Refer to Corteva's Form 10 registration statement filed on May 6, 2019, which can be found on the investors section of the Corteva website, for further details on the above transactions. The pro forma financial statements were prepared in accordance with Article 11 of Regulation S-X, and are presented for informational purposes only, and do not purport to project the results of operations would have been had the above actually occurred on the dates indicated, nor do they purport to project the results of operations for any future period or as of any future date.

Regulation G (Non-GAAP Financial Measures)

This earnings release includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures include organic sales, operating EBITDA, pro forma operating EBITDA, operating EBITDA margin, pro forma operating EBITDA margin, operating earnings per share, pro forma operating earnings per share, base tax rate, and pro forma base tax rate. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results. These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page 5 of the Financial Statement Schedules. For first quarter and prior year, these non-GAAP measures are being reconciled to a pro forma GAAP financial measure prepared and presented in accordance with Article 11 of Regulation S-X. See Article 11 Pro Forma Combined Statements of Operations starting on page 15 of the Financial Statement Schedules.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures to their most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the company's control, such as Significant Items, without unreasonable effort. For Significant items reported in the periods presented, refer to page 8 of the Financial Statement Schedules. Beginning January 1, 2020, the company will present accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the noncash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® Roundup Ready 2 Xtend® herbicide tolerance traits. During the five-year ramp-up period of Enlist E3TM, Corteva is expected to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits peginning in 2021, with expected minimal use of the trait platform after the completion of the ramp-up.

Organic sales is defined as price and volume and excludes currency and portfolio impacts. Operating EBITDA is defined as earnings (i.e., income from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits, net and foreign exchange gains (losses), excluding the impact of significant items (including goodwill impairment charges). Non-operating benefits, net consists of non-operating pension and other post-employment benefit (OPEB) credits, tax indemnification adjustments, environmental remediation and legal costs associated with legacy businesses and sites of Historical DuPont. Tax indemnification adjustments, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Operating EBITDA margin is defined as Operating EBITDA as a percentage of net sales. Operating earnings per share are defined as "Earnings per common share from continuing operations - diluted" excluding the after-tax impact of significant items (including goodwill impairment charges), the after-tax impact of non-operating benefits, net, and the after-tax impact of significant items (including goodwill impairment charges), the after-tax impact of non-operating benefits, net, and the after-tax impact of amortization expense associated from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible enset is defined as the effective tax rate excluding the impacts of foreign exchange gains (losses), non-operating benefits, net, and the paragraph 'Corteva Unaudited Pro Forma Financial Information'.

® TM SM Trademarks and service marks of Dow AgroSciences, DuPont or Pioneer, and their affiliated companies or their respective owners.

###

01/30/2020

Media Contact:

Gregg M. Schmidt +1 302-485-3260 gregg.m.schmidt@corteva.com Investor Contact: Megan Britt +1 302-485-3279 megan.britt@corteva.com

1 Corteva, Inc. Consolidated Statements of Operations (Dollars in millions, except per share amounts)

	т	Three Months Ended December 31,		Twelve Months End December 31,		ded		
		2019		2018		2019		2018
Net sales	\$	2,983	\$	2,815	\$	13,846	\$	14,287
Cost of goods sold		1,968		2,024		8,575		9,948
Research and development expense		290		345		1,147		1,355
Selling, general and administrative expenses		747		694		3,065		3,041
Amortization of intangibles		161		107		475		391
Restructuring and asset related charges - net		55		228		222		694
Integration and separation costs		50		295		744		992
Goodwill impairment charge		_		_		-		4,503
Other income - net		125		131		215		249
Loss on early extinguishment of debt		_		81		13		81
Interest expense		24		86		136		337
Loss from continuing operations before income taxes		(187)		(914)		(316)		(6,806)
(Benefit from) provision for income taxes on continuing operations		(145)		156		(46)		(31)
Loss from continuing operations after income taxes		(42)		(1,070)		(270)		(6,775)
Income (loss) from discontinued operations after income taxes		24		548		(671)		1,748
Net loss		(18)		(522)		(941)		(5,027)
Net income attributable to noncontrolling interests		3		9		18		38
Net loss attributable to Corteva	\$	(21)	\$	(531)	\$	(959)	\$	(5,065)
Basic loss per share of common stock:								
Basic loss per share of common stock from continuing operations	\$	(0.06)	\$	(1.44)	\$	(0.38)	\$	(9.08)
Basic earnings (loss) per share of common stock from discontinued operations		0.03		0.73		(0.90)		2.32
Basic loss per share of common stock	\$	(0.03)	\$	(0.71)	\$	(1.28)	\$	(6.76)
Diluted loss per share of common stock:								
Diluted loss per share of common stock from continuing operations	\$	(0.06)	\$	(1.44)	\$	(0.38)	\$	(9.08)
Diluted earnings (loss) per share of common stock from discontinued operations	-	0.03	-	0.73	-	(0.90)		2.32
Diluted loss per share of common stock	\$	(0.03)	\$	(0.71)	\$	(1.28)	\$	(6.76)
	÷	()	<u> </u>	()	<u> </u>	(÷	(
Average number of shares outstanding used in earnings per share (EPS) calculation (in millions) ¹								
Average number of shares outstanding used in earnings per share (EPS) calculation (in millions) ¹ Basic		749.6		749.4		749.5		749.4

1. On June 1, 2019, DuPont de Nemours, Inc. ("DuPont") distributed 748,815,000 shares of Corteva, Inc. common stock to holders of its common stock. Basic and diluted (loss) earnings per common share for the three and twelve months ended December 31, 2018 were calculated using the shares distributed on June 1, 2019 plus 582,000 of additional shares in which accelerated vesting conditions have been met.

2 Corteva, Inc. Condensed Consolidated Balance Sheets (Dollars in millions, except per share amounts)

	December 31, 2019		December 31, 2018
Assets			
Current assets			
Cash and cash equivalents	\$ 1,	64 \$	2,270
Marketable securities		5	5
Accounts and notes receivable, net	5,1	28	5,260
Inventories	5,0	32	5,310
Other current assets	1,	90	1,038
Assets of discontinued operations - current			9,089
Total current assets	13,	19	22,972
Investment in nonconsolidated affiliates		66	138
Property, plant and equipment, net of accumulated depreciation December 31, 2019 - \$3,326 and December 31, 2018 - \$2,796	4,	46	4,544
Goodwill	10,1	29	10,193
Other intangible assets	11,-	24	12,055
Deferred income taxes	:	87	304
Other assets	2,	26	1,932
Assets of discontinued operations - noncurrent		_	56,545
Total Assets	\$ 42,5	97 \$	108,683
Liabilities and Equity			
Current liabilities			
Short-term borrowings and finance lease obligations	\$	7 \$	2,154
Accounts payable	3,	02	3,798
Income taxes payable		95	186
Accrued and other current liabilities	4,	34	4,005
Liabilities of discontinued operations - current		_	3,167
Total current liabilities		38	13,310
Long-Term Debt		15	5,784
Other Noncurrent Liabilities			
Deferred income tax liabilities		20	1,480
Pension and other post employment benefits - noncurrent	6.	.77	5,677
Other noncurrent obligations	2,	92	1,795
Liabilities of discontinued operations - noncurrent			5,484
Total noncurrent liabilities	9,	04	20,220
Commitments and contingent liabilities			
Stockholders' equity			
Common stock, \$0.01 par value; 1,666,667,000 shares authorized; issued at December 31, 2019 - 748,577,000		7	_
Additional paid-in capital	27,	97	_
Divisional equity		_	78,020
Accumulated deficit	(4	-25)	_
Accumulated other comprehensive loss	(3,	-	(3,360)
Total Corteva stockholders' equity	24,		74,660
Noncontrolling interests		46	493
Total equity	24,	55	75,153
Total Liabilities and Equity	\$ 42,		

3 Corteva, Inc. Pro Forma Consolidated Statements of Operations¹ (Dollars in millions, except per share amounts)

	Three Months Ended December 31,			Twelve Months Ended December 31,			
	2019 ²		2018		2019		2018
Net sales	\$ 2,983	\$	2,815	\$	13,846	\$	14,287
Cost of goods sold	1,968		1,906		8,386		8,449
Research and development expense	290		344		1,147		1,352
Selling, general and administrative expenses	747		694		3,068		3,042
Amortization of intangibles	161		107		475		391
Restructuring and asset related charges - net	55		228		222		694
Integration and separation costs	50		187		632		571
Goodwill impairment charge	_		—		_		4,503
Other income - net	125		131		215		249
Loss on early extinguishment of debt	—		—		13		_
Interest expense	24		25		91		76
(Loss) income from continuing operations before income taxes	(187)		(545)		27		(4,542)
(Benefit from) provision for income taxes on continuing operations	(145)		201		1		395
(Loss) income from continuing operations after income taxes	 (42)		(746)		26		(4,937)
Net income from continuing operations attributable to noncontrolling interests	 3		6		13		29
Net (loss) income from continuing operations attributable to Corteva	\$ (45)	\$	(752)	\$	13	\$	(4,966)
Basic (loss) earnings per share of common stock from continuing operations	\$ (0.06)	\$	(1.00)	\$	0.02	\$	(6.63)
Diluted (loss) earnings per share of common stock from continuing operations	\$ (0.06)	\$	(1.00)	\$	0.02	\$	(6.63)
Average number of shares outstanding used in earnings per share (EPS) calculation (in millions) ³							
Basic	749.6		749.4		749.5		749.4
Diluted	749.6		749.4		749.5		749.4

See Article 11 Pro Forma Combined Statements of Operations beginning on page 15.
 The three months ended December 31, 2019 are on an as reported basis.
 On June 1, 2019, DuPont distributed 748,815,000 shares of Corteva, Inc. common stock to holders of its common stock. Basic and diluted (loss) earnings per common share for the three and twelve months ended December 31, 2018 were calculated using the shares distributed on June 1, 2019 plus 582,000 of additional shares in which accelerated vesting conditions have been met.

4 Corteva, Inc. Consolidated Segment Information (Dollars in millions)

		ed	Twelve Months Ended December 31,					
SEGMENT NET SALES - SEED		2019		2018		2019		2018
Corn	\$	962	\$	891	\$	5,111	\$	5,180
Soybean		74		45		1,371		1,494
Other oilseeds		92		93		561		607
Other		115		97		547		561
Seed	\$	1,243	\$	1,126	\$	7,590	\$	7,842
		Three Mo Decen	nths Endo 1ber 31,	ed		Twelve M Decer	onths End nber 31,	ed
SEGMENT NET SALES - CROP PROTECTION		2019		2018		2019		2018
Herbicides	\$	871	\$	836	\$	3,270	\$	3,415
Insecticides		494		395		1,652		1,506
Fungicides		305		303		1,081		1,142
Other		70		155		253		382
Crop Protection	\$	1,740	\$	1,689	\$	6,256	\$	6,445
		Three Mo Decen	nths Endo 1ber 31,	ed		Twelve Me Decer	onths End nber 31,	ed
GEOGRAPHIC NET SALES - SEED		2019		2018		2019		2018
North America ¹	\$	486	\$	384	\$	4,724	\$	4,974
EMEA ²		178		186		1,378		1,408
Asia Pacific		85		86		358		358
Latin America		494		470		1,130		1,102
Rest of World ³		757		742		2,866		2,868
Net Sales	\$	1,243	\$	1,126	\$	7,590	\$	7,842
		Three Mo Decen	nths Endo 1ber 31,	ed		Twelve Me Decer	onths End nber 31,	ed
GEOGRAPHIC NET SALES - CROP PROTECTION		2019		2018		2019		2018
North America ¹	\$	643	\$	594	\$	2,205	\$	2,438
EMEA ²		226		200		1,362		1,357
Asia Pacific		256		282		930		935
Latin America		615		613		1,759		1,715
Rest of World ³		1,097		1,095		4,051		4,007
Net Sales	\$	1,740	\$	1,689	\$	6,256	\$	6,445

^{1.} Reflects U.S. & Canada

^{2.} Reflects Europe, Middle East, and Africa

^{3.} Reflects EMEA, Latin America, and Asia Pacific

5 Corteva, Inc. Corteva, Inc. Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)

		nths Ended nber 31,		Twelve Months Ended December 31,					
	 2019	2	018		2019		2018		
OPERATING EBITDA	As Reported	Pro	Forma		Pro Forma		Pro Forma		
Seed	\$ (26)	\$	(87)	\$	1,040	\$	1,139		
Crop Protection	277		169		1,066		1,074		
Corporate Expenses	(27)		(32)		(119)		(141)		
Operating EBITDA (Non-GAAP)	\$ 224	\$	50	\$	1,987	\$	2,072		
		nths Ended aber 31,			Twelve Mo Decen				
	2019	2	018		2019		2018		
RECONCILIATION OF (LOSS) INCOME FROM CONTINUING OPERATIONS AFTER INCOME TAXES TO OPERATING EBITDA	 As Reported	Pro	Forma		Pro Forma		Pro Forma		
(Loss) income from continuing operations after income taxes (GAAP)	\$ (42)	\$	(746)	\$	26	\$	(4,937)		
(Benefit from) provision for income taxes on continuing operations	(145)		201		1		395		
(Loss) income from continuing operations before income taxes (GAAP)	 (187)		(545)		27		(4,542)		
Depreciation and amortization	289		242		1,000		909		
Interest income	(13)		(23)		(59)		(86)		
Interest expense	24		25		91		76		
Exchange losses (gains) - net ¹	29		(63)		66		77		
Non-operating benefits - net ²	(23)		(56)		(129)		(211)		
Goodwill impairment charge	—		—		—		4,503		
Significant items charge ³	105		470		991		1,346		
Operating EBITDA (Non-GAAP)	224		50		1,987		2,072		

Refer to page 14 for pre-tax and after tax impacts of exchange losses (gains) - net.
 Non-operating benefits—net consists of non-operating pension and other post-employment benefit (OPEB) (benefits) costs, tax indemnification adjustments, environmental remediation and legal costs associated with legacy EID businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.
 Refer to page 8 for pre-tax and after tax impacts of significant items.

6 Corteva, Inc. Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)

PRICE - VOLUME - CURRENCY ANALYSIS REGION

		Q4 2019 vs. Q4	2018		Percent Change Due To:							
	 Net Sales Change	(GAAP)	Organic Change ¹ (f	Non-GAAP)	Local Price &			Portfolio /				
	 \$	%	\$	%	Product Mix	Volume	Currency	Other				
North America	\$ 151	15 % \$	156	16 %	2 %	14 %	— %	(1)%				
EMEA	18	5 %	25	7 %	4 %	3 %	(2)%	— %				
Asia Pacific	(27)	(7)%	(23)	(6)%	(2)%	(4)%	1 %	(2)%				
Latin America	26	2 %	95	8 %	4 %	4 %	(6)%	— %				
Rest of World	 17	1 %	97	5 %	3 %	2 %	(4)%	— %				
Total	\$ 168	6 % \$	253	9 %	3 %	6 %	(3)%	— %				

SEED

		Q4 2019 vs. Q4 20	18		Percent Change Due To:							
	 Net Sales Change (O	GAAP)	Organic Change ¹ (N	on-GAAP)	Local Price &			Portfolio /				
	 \$	%	\$	%	Product Mix	Volume	Currency	Other				
North America	\$ 102	27 % \$	100	26 %	10 %	16 %	—%	1 %				
EMEA	(8)	(4)%	(7)	(3)%	(1)%	(2)%	(1)%	%				
Asia Pacific	(1)	(1)%	(4)	(4)%	(2)%	(2)%	3 %	— %				
Latin America	 24	5 %	53	11 %	12 %	(1)%	(6)%	%				
Rest of World	 15	2 %	42	6 %	7 %	(1)%	(4)%	— %				
Total	\$ 117	10 % \$	142	13 %	8 %	5 %	(3)%	—%				

CROP PROTECTION

		Q4 2019 vs. Q4 20	18		Percent Change Due To:							
	 Net Sales Change	(GAAP)	Organic Change ¹ (No	on-GAAP)	Local Price &			Portfolio /				
	 \$	%	\$	%	Product Mix	Volume	Currency	Other				
North America	\$ 49	8 % \$	56	9 %	(4)%	13 %	— %	(1)%				
EMEA	26	13 %	32	16 %	9 %	7 %	(3)%	— %				
Asia Pacific	(26)	(9)%	(19)	(7)%	(2)%	(5)%	1 %	(3)%				
Latin America	2	%	42	7 %	(1)%	8 %	(7)%	%				
Rest of World	 2	— %	55	5 %	1 %	4 %	(4)%	(1)%				
Total	\$ 51	3 % \$	111	7 %	(1)%	8 %	(3)%	(1)%				

7 Corteva, Inc. Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)

<u> PRICE - VOLUME - CURRENCY ANALYSIS</u> <u>REGION</u>

<u>ILLOION</u>													
	 Т	welve Months 2019 vs. Twe	lve Months 2018		Percent Change Due To:								
	Net Sales Change	e (GAAP)	Organic Change ¹ (N	Non-GAAP)	Local Price &			Portfolio /					
	\$	%	\$	%	Product Mix	Volume	Currency	Other					
North America	\$ (483)	(7)% \$	(448)	(6)%	(2)%	(4)%	(1)%	—%					
EMEA	(25)	(1)%	189	7 %	2 %	5 %	(8)%	—%					
Asia Pacific	(5)	— %	43	3 %	2 %	1 %	(3)%	— %					
Latin America	72	3 %	208	8 %	4 %	4 %	(5)%	—%					
Rest of World	42	1 %	440	7 %	3 %	4 %	(6)%	—%					
Total	\$ (441)	(3)% \$	(8)	%	%	%	(3)%	%					

SEED

	Two	elve Months 2019 vs. Twelv	e Months 2018		Percent Change Due To:							
	Net Sales Change (GAAP)	Organic Change ¹ (N	lon-GAAP)	Local Price &			Portfolio /				
	\$	%	\$	%	Product Mix	Volume	Currency	Other				
North America	\$ (250)	(5)% \$	(237)	(5)%	(2)%	(3)%	%	—%				
EMEA	(30)	(2)%	85	6 %	1 %	5 %	(8)%	%				
Asia Pacific	-	%	14	4 %	2 %	2 %	(4)%	%				
Latin America	28	3 %	82	7 %	8 %	(1)%	(4)%	%				
Rest of World	(2)	%	181	6 %	4 %	2 %	(6)%	—%				
Total	\$ (252)	(3)% \$	(56)	(1)%	%	(1)%	(2)%	%				

CROP PROTECTION

	 Tw	elve Months 2019 vs. Twel	ve Months 2018		Percent Change Due To:							
	 Net Sales Change ((GAAP)	Organic Change ¹ (N	on-GAAP)	Local Price &			Portfolio /				
	 \$	%	\$	%	Product Mix	Volume	Currency	Other				
North America	\$ (233)	(10)% \$	(211)	(9)%	(3)%	(6)%	%	(1)%				
EMEA	5	%	104	7 %	2 %	5 %	(7)%	— %				
Asia Pacific	(5)	(1)%	29	3 %	3 %	%	(3)%	(1)%				
Latin America	44	3 %	126	8 %	1 %	7 %	(5)%	— %				
Rest of World	 44	1 %	259	7 %	2 %	5 %	(5)%	(1)%				
Total	\$ (189)	(3)% \$	48	1 %	%	1 %	(3)%	(1)%				

1. Organic sales is defined as price and volume and excludes currency and portfolio impacts.

8 Corteva, Inc. Significant Items (Dollars in millions, except per share amounts)

SIGNIFICANT ITEMS BY SEGMENT (PRE-TAX)

		Three Mo Decen				Months Ended ember 31,		
		2019	2018			2019		2018
	As	Reported		Pro Forma	1	Pro Forma		Pro Forma
Seed	\$	(90)	\$	(150)	\$	(304)	\$	(399)
Crop Protection		1		(16)		(23)		(58)
Corporate		(16)		(304)		(664)		(889)
Total significant items before income taxes	\$	(105)	\$	(470)	\$	(991)	\$	(1,346)

SIGNIFICANT ITEMS - PRE-TAX, AFTER TAX, AND EPS IMPACTS

		Pre-tax			After tax ¹⁰					(\$ Per Share) ¹¹			
		2019	c tus	2018		2019	. un	2018		2019	onurc)	2018	
1st Quarter	_	Pro Forma		Pro Forma		Pro Forma		Pro Forma		Pro Forma		Pro Forma	
Integration costs ¹	\$	(100)	\$	(124)	\$	(16)	\$	(93)	\$	(0.02)	\$	(0.12)	
Restructuring and asset related charges, net ²		(61)		(130)		(53)		(100)		(0.07)		(0.13)	
Loss on divestiture ³		(24)		_		(24)		_		(0.03)		_	
Income tax items ⁴		_		(50)		_		(102)		_		(0.14)	
1st Quarter - Total	\$	(185)	\$	(304)	\$	(93)	\$	(295)	\$	(0.12)	\$	(0.39)	
2nd Quarter		As Reported		Pro Forma	1	As Reported	Р	ro Forma	A	As Reported	I	Pro Forma	
Integration and separation costs ¹	\$	(330)	\$	(126)	\$	(436)	\$	(97)	\$	(0.58)	\$	(0.13)	
Restructuring and asset related charges, net ²		(60)		(101)		(48)		(81)		(0.06)		(0.11)	
Gain on sale of assets ⁵		_		24		_		19		_		0.03	
Amortization of inventory step up ⁶		(52)		_		(41)		_		(0.06)		_	
Loss on early extinguishment of debt7		(13)		_		(10)		_		(0.01)		_	
Income tax items ⁴		_		_		-		(7)		_		(0.01)	
2nd Quarter - Total	\$	(455)	\$	(203)	\$	(535)	\$	(166)	\$	(0.71)	\$	(0.22)	
<u>3rd Quarter</u>		As Reported		Pro Forma	1	As Reported	Р	ro Forma	A	As Reported	I	Pro Forma	
Integration and separation costs ¹	\$	(152)	\$	(134)	\$	(119)	\$	(162)	\$	(0.16)	\$	(0.22)	
Restructuring and asset related charges, net ²		(46)		(235)		(34)		(192)		(0.04)		(0.26)	
Amortization of inventory step up 6		(15)		—		(15)		—		(0.02)		—	
Argentina currency devaluation ⁸		(33)		—		(38)		—		(0.05)		_	
Income tax items ⁴		—		—		38		(2)		0.05		—	
3rd Quarter - Total	\$	(246)	\$	(369)	\$	(168)	\$	(356)	\$	(0.22)	\$	(0.48)	
4th Quarter		As Reported		Pro Forma	1	As Reported	Р	ro Forma	A	As Reported	H	Pro Forma	
Integration and separation costs ¹	\$	(50)	\$	(187)	\$	20	\$	(147)	\$	0.03	\$	(0.20)	
Restructuring and asset related charges, net ²		(55)		(228)		(42)		(172)		(0.06)		(0.23)	
Loss on divestiture ³		—		(2)		—		(3)		—		—	
Loss on deconsolidation of subsidiary 9		_		(53)		—		(41)		—		(0.05)	
Income tax items ⁴		_		—		34		(274)		0.05		(0.37)	
4th Quarter - Total	\$	(105)	\$	(470)	\$	12	\$	(637)	\$	0.02	\$	(0.85)	
Year-to-date Total ¹¹	\$	(991)	\$	(1,346)	\$	(784)	\$	(1,454)	\$	(1.04)	\$	(1.94)	

Corteva, Inc. Significant Items (Dollars in millions, except per share amoun

1. Integration and separation costs is included in "Integration and separation costs" on the Consolidated Statement of Operations. Beginning in Q2 2019, this includes both integration and separation costs.

The after tax benefit for the fourth quarter of 2019 includes a net tax benefit of \$48 related to application of the U.S. Tax Reform's foreign tax provisions.

The after tax charge for the third quarter of 2019 includes a net tax benefit of \$13 related to application of the U.S. Tax Reform's foreign tax provisions.

The after tax charge for the second quarter of 2019 includes a net tax charge of \$(114) related to U.S. state blended tax rate changes associated with the Business Separations and a net tax charge of \$(96) related to application of the U.S. Tax Reform's foreign tax provisions.

The after tax charge for the first quarter of 2019 includes a net tax charge of \$(32) related to U.S. state blended tax rate changes associated with the Business Separations and a tax benefit of \$102 related to an internal legal entity restructuring associated with the Business Separations.

2. Fourth quarter, shird quarter, second quarter, and first quarter 2019 included restructuring and asset related charges of \$(55), \$(46), \$(60) and \$(61), respectively. The charge for the fourth quarter included a \$(90) non-cash intangible asset impairment charge as a result of the company's decision to accelerate the ramp up of the Enlist E3TM trait platform in the company's soybean portfolio mix across all brands, including Pioneer brands, over the next five years with minimal use of the Roundup Ready 2 Yield[®] and Roundup Ready 2 Xtend[®] traits thereafter for the remainder of the Roundup Ready 2 License Agreement. This charge was partially offset by a benefit of \$12 associated with the DowDuPont Cost Synergy Program and a benefit of \$13 associated with the DowDuPont Agriculture Division Restructuring Program. The charge for the third quarter included a \$(54) non-cash asset impairment related to certain intangible assets that primarily relate to heritage Dow AgroSciences intangibles previously acquired from Cooperativa Central de Pesquisa Agricola's ("Coodetec"), classified as developed technology, other intangible assets and in-process research and development ("IPR&D"), partially offset by a benefit of \$8 associated with the DowDuPont Cost Synergy Program. The charge for the first and second quarter is primarily related to the DowDuPont Cost Synergy Program.

Fourth quarter, third quarter, second quarter, and first quarter 2018 included restructuring and asset related charges of \$(228), \$(235), \$(101) and \$(130), respectively. The charges for the first and second quarter primarily related to the DowDuPont Cost Synergy Program. The charges for the third quarter included a \$(109) charge related to the DowDuPont Cost Synergy Program, an \$(85) non-cash asset impairment related to certain IPR&D intangibles, and a \$(41) other than temporary non-cash impairment related to an investment in nonconsolidated affiliates in China. The charges for the fourth quarter consisted of a \$(144) charge related to the DowDuPont Cost Synergy Program and an \$(84) charge related to the DowDuPont Agriculture Division Restructuring Program.

3. First quarter 2019 included a loss of \$(24) included in other income - net related to Historical Dow's sale of a joint venture related to synergy actions.

Fourth quarter 2018 includes a \$(2) loss related to an asset sale.

4. Fourth quarter 2019 includes an after tax benefit related to the impact of the release of a tax valuation allowance recorded against the net deferred tax asset position of a Swiss legal entity.

Third quarter 2019 includes an after tax benefit related to Swiss Tax Reform.

Fourth quarter 2018 relates to effects of U.S. tax reform.

Third quarter 2018 includes an after tax benefit related to the impacts of a tax valuation allowance recorded against the net deferred tax asset position of a Brazilian legal entity (\$75 expense), a tax charge related to an internal legal entity restructuring associated with the Business Separations (\$25 expense), and U.S. Tax Reform (\$16 expense), which were almost entirely offset by the impact of the company's discretionary pension contribution in 2018 which was deducted on a 2017 tax return (\$114 benefit).

Second quarter 2018 relates to effects of U.S. tax reform.

10 Corteva, Inc. Significant Items (Dollars in millions, except per share amounts)

First quarter 2018 includes a \$(50) pre-tax foreign exchange loss related to adjustments to foreign currency exchange contracts as a result of U.S. tax reform and a \$(64) after tax charge related to effects of U.S. tax reform.

- 5. Second quarter 2018 includes a gain of \$24 included in other income net related to an asset sale.
- 6. Third quarter and second quarter 2019 include amortization of inventory step up of \$(15) and \$(52), respectively, included in cost of goods sold related to the amortization of the inventory step-up in connection with the Merger.
- 7. Second quarter 2019 includes a loss on the early extinguishment of debt related to the difference between the redemption price and the par value of the Make Whole Notes and Term Loan Facility, partially offset by the write-off of unamortized step-up related to the fair value step-up of EID's debt.
- 8. Third quarter 2019 includes a \$(33) loss included in other income net associated with remeasuring the company's Argentine Peso net monetary assets, resulting from an unexpected August primary election result in Argentina. Throughout the three months ended September 30, 2019, the Argentine Peso dropped approximately a third of its value against the U.S. dollar and in September of 2019, the country's central bank announced new restrictions on foreign currency transactions. The after tax charge of \$(38) includes a tax valuation allowance recorded against the net deferred tax asset position of an Argentine legal entity.
- 9. Fourth quarter 2018 includes a loss related to the deconsolidation of a subsidiary.
- 10. Unless specifically addressed in notes above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
- 11. Earnings per share for the year may not equal the sum of quarterly earnings per share due to rounding and the changes in average share calculations.

11 Corteva, Inc. Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)

Operating Earnings (Loss) Per Share (Non-GAAP)

Operating earnings (loss) per share is defined as earnings per share from continuing operations – diluted, excluding non-operating benefits - net, amortization of intangibles (existing as of Separation), significant items, and goodwill impairment charges.

		Three Mon Decem		d	
	 2019	2018 ²		2019	2018 ²
	 \$	\$		EPS (diluted)	 EPS (diluted)
Net loss from continuing operations attributable to Corteva (GAAP)	\$ (45)	\$ (752)	\$	(0.06)	\$ (1.00)
Less: Non-operating benefits - net, after tax 1	16	44		0.02	0.06
Less: Amortization of intangibles (existing as of Separation), after tax	(126)	(86)		(0.17)	(0.11)
Less: Significant items benefit (charge), after tax	12	(637)		0.02	(0.85)
Operating Earnings (Loss) (Non-GAAP)	\$ 53	\$ (73)	\$	0.07	\$ (0.10)
		Twelve Mo	nthe Ende	a	
		Decem		u.	
	 2019 ²			2019 ²	 2018 ²
	 2019 ² \$	 Decem		-	 2018 ² EPS (diluted)
Net income (loss) from continuing operations attributable to Corteva (GAAP)	\$ 	\$ Decem		2019 ²	\$
Net income (loss) from continuing operations attributable to Corteva (GAAP) Less: Non-operating benefits - net, after tax ¹	\$ \$	\$ Decem 2018 ² \$		2019 ² EPS (diluted)	\$ EPS (diluted)
	\$ \$ 13	\$ Decem 2018 ² \$ (4,966)		2019² EPS (diluted) 0.02	\$ EPS (diluted) (6.63)
Less: Non-operating benefits - net, after tax ¹	\$ \$ 13 100	\$ Decem 2018 ² \$ (4,966) 165		2019 ² EPS (diluted) 0.02 0.13	\$ EPS (diluted) (6.63) 0.22
Less: Non-operating benefits - net, after tax ¹ Less: Amortization of intangibles (existing as of Separation), after tax	\$ \$ 13 100 (376)	\$ Decem 2018 ² \$ (4,966) 165 (313)		2019 ² EPS (diluted) 0.02 0.13 (0.50)	\$ EPS (diluted) (6.63) 0.22 (0.42)

1. Non-operating benefits (OPEB) benefits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy EID businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. 2. Periods are presented on a Pro Forma Basis, prepared in accordance with Article 11 of Regulation S-X.

12 Corteva, Inc. Operating EBITDA to Operating Earnings Per Share (Dollars in millions, except per share amounts)

Operating EBITDA to Operating Earnings (Loss) Per Share

	Three Mor Decem			Twelve Months Ended December 31,			
	 2019	2018	 2019		2018		
	 As Reported		Pro Forma	 Pro Forma		Pro Forma	
Operating EBITDA (Non-GAAP) ¹	\$ 224	\$	50	 1,987		2,072	
Depreciation	(128)		(135)	(525)		(518)	
Interest Income	13		23	59		86	
Interest Expense	(24)		(25)	(91)		(76)	
(Provision for) benefit from income taxes on continuing operations before significant items, goodwill impairment charges, non-operating benefits - net, amortization of intangibles (existing as of Separation), and exchange (gains)							
losses, net (Non-GAAP)	(15)		35	(280)		(255)	
Base income tax rate from continuing operations (Non-GAAP) ¹	17.6%		40.2%	19.6%		16.3%	
Exchange losses - net, after tax ²	(14)		(15)	(64)		(141)	
Net income attributable to non-controlling interests	(3)		(6)	(13)		(29)	
Operating Earnings (Loss) (Non-GAAP) ¹	\$ 53	\$	(73)	\$ 1,073	\$	1,139	
Diluted Shares (in millions)	749.6		749.4	749.5		749.4	
Operating Earnings (Loss) Per Share (Non-GAAP) ¹	\$ 0.07	\$	(0.10)	\$ 1.43	\$	1.52	
 Refer to pages 5, 11, and 13 for Non-GAAP reconciliations. Refer to page 14 for pre-tax and after tax impacts of exchange gains (losses) - net. 							

13 Corteva, Inc. Reconciliation of Non-GAAP Measures (Dollars in millions)

Reconciliation of Base Income Tax Rate to Effective Income Tax Rate

Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), significant items, goodwill impairment charges, amortization of intangibles (existing as of Separation), and non-operating benefits - net.

	Three Months Ended December 31,			Twelve Months Ended December 31,				
		2019		2018		2019		2018
	A	s Reported		Pro Forma		Pro Forma		Pro Forma
(Loss) income from continuing operations before income taxes (GAAP)	\$	(187)	\$	(545)	\$	27	\$	(4,542)
Add: Significant items - charge ¹		105		470		991		1,346
Goodwill impairment charge		_		—		_		4,503
Non-operating benefits - net		(23)		(56)		(129)		(211)
Amortization of intangibles (existing as of Separation)		161		107		475		391
Less: Exchange (losses) gains, net ²		(29)		63		(66)		(77)
Income (loss) from continuing operations before income taxes, significant items, goodwill impairment charges, non-operating benefits - net, amortization of intangibles (existing as of Separation), and exchange (gains) losses, net (Non-GAAP)	\$	85	\$	(87)	\$	1,430	\$	1,564
(Benefit from) provision for income taxes on continuing operations (GAAP)	\$	(145)	\$	201	\$	1	\$	395
Add: Tax benefits (expenses) on significant items charge		117		(167)		207		(108)
Tax expenses on goodwill impairment charge		—		—		-		-
Tax expenses on non-operating benefits - net		(7)		(12)		(29)		(46)
Tax benefits on amortization of intangibles (existing as of Separation)		35		21		99		78
Tax benefits (expenses) on exchange gains (losses), net		15		(78)		2		(64)
Provision for (benefit from) income taxes on continuing operations before significant items, goodwill impairment charges, non-operating benefits - net, amortization of intangibles (existing as of Separation), and exchange (gains) losses, net (Non-GAAP)	\$	15	\$	(35)	\$	280	\$	255
Effective income tax rate (GAAP)		77.5 %		(36.9)%		3.7 %		(8.7)%
Significant items, goodwill impairment charge, non-operating benefits, and amortization of intangibles (existing as of Separation) effect		(77.5)%		(142.3)%		16.7 %		30.2 %
Tax rate from continuing operations before significant items, goodwill impairment charge, non-operating benefits - net, and amortization of intangibles (existing as of Separation)		%		(179.2)%		20.4 %		21.5 %
Exchange gains (losses), net effect		17.6 %		219.4 %		(0.8)%		(5.2)%
Base income tax rate from continuing operations (Non-GAAP)		17.6 %		40.2 %		19.6 %		16.3 %

1. See Significant Items table for further detail.

2. Pre-tax exchange gains (losses), net for the twelve months ended December 31, 2019, on an operating earnings basis (Non-GAAP), exclude a \$(33) exchange loss associated with the devaluation of the Argentine peso. Pre-tax exchange loss, net for the twelve months ended December 31, 2018, on an operating earnings basis (Non-GAAP), excludes a \$(50) exchange loss related to adjustments to foreign currency exchange contracts as a result of U.S. tax reform.

14 Corteva, Inc. (Dollars in millions, except per share amounts)

Exchange Gains/Losses

The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The hedging program gains (losses) are largely taxable (tax deductible) in the United States (U.S.), whereas the offsetting exchange gains (losses) on the remeasurement of the net monetary asset positions are often not taxable (tax deductible) in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in other income (expense) - net and the related tax impact is recorded in provision for (benefit from) income taxes on continuing operations in the Consolidated Statements of Operations.

		Three Mo Decen	l	Twelve Months Ended December 31,						
		2019		2018		2019		2018		
Subsidiary Monetary Position Gain (Loss)										
Pre-tax exchange gains (losses)	\$	18	\$	(4)	\$	(8)	\$	(221)		
Local tax benefits (expenses)		4		(63)		(11)		(31)		
Net after tax impact from subsidiary exchange gains (losses)	S	22	\$	(67)	\$	(19)	\$	(252)		
Hedging Program (Loss) Gain										
Pre-tax exchange (losses) gains	\$	(47)	\$	67	\$	(58)	\$	144		
Tax benefits (expenses)		11		(15)		13		(33)		
Net after tax impact from hedging program exchange (losses) gains	\$	(36)	\$	52	\$	(45)	\$	111		
Total Exchange (Loss) Gain										
Pre-tax exchange (losses) gains ¹	\$	(29)	\$	63	\$	(66)	\$	(77)		
Tax benefits (expenses)		15		(78)		2		(64)		
Net after tax exchange losses	\$	(14)	\$	(15)	\$	(64)	\$	(141)		

As shown above, the "Total Exchange (Loss) Gain" is the sum of the "Subsidiary Monetary Position Loss" and the "Hedging Program Gain (Loss)."

1. Pre-tax exchange (losses) gains, net for the twelve months ended December 31, 2019, on an operating earnings basis (Non-GAAP), excludes a \$(33) exchange loss associated with the devaluation of the Argentine peso. Pre-tax exchange loss, net for the twelve months ended December 31, 2018, on an operating earnings basis (Non-GAAP), excludes a \$(50) exchange loss related to adjustments to foreign currency exchange contracts as a result of U.S. tax reform.

15 Corteva, Inc. Article 11 Pro Forma Combined Statement of Operations (Dollars in millions, except per share amounts)

					Months Ended nber 31, 2018				
				Α	djustments				
	As I	Reported Corteva	 Merger ¹	Deb	t Retirement ²	Sepa	rations Related ³	Pro F	orma Corteva
Net sales	\$	2,815	\$ _	\$	_	\$	_	\$	2,815
Cost of goods sold		2,024	(130)		—		12		1,906
Research and development expense		345	—		—		(1)		344
Selling, general and administrative expenses		694	_		—		—		694
Amortization of intangibles		107	—		—		—		107
Restructuring and asset related charges - net		228	_		_		—		228
Integration and separation costs		295	_		_		(108)		187
Other income - net		131	_		_		—		131
Loss on early extinguishment of debt		81	_		(81)		_		_
Interest expense		86	_		(61)		—		25
Loss from continuing operations before income taxes		(914)	 130		142		97		(545)
Provision for income taxes on continuing operations		156	31		32		(18)		201
Loss from continuing operations after income taxes		(1,070)	 99		110		115		(746)
Net income from continuing operations attributable to noncontrolling interests		6	 						6
Net loss from continuing operations attributable to Corteva	\$	(1,076)	\$ 99	\$	110	\$	115	\$	(752)
Basic loss per share of common stock from continuing operations	\$	(1.44)						\$	(1.00)
Diluted loss per share of common stock from continuing operations	\$	(1.44)						\$	(1.00)
Average number of shares outstanding used in earnings per share (EPS) calculation (in millions):									
Basic		749.4							749.4
Diluted		749.4							749.4

Related to the amortization of EID's agriculture business' inventory step-up recognized in connection with the Merger, as the incremental amortization is directly attributable to the Merger and will not have a continuing impact.
 Represents removal of interest expense related to the debt redemptions/repayments and the removal of loss on extinguishment of debt related to the difference between the redemption price and the par value of the Make Whole Notes, the Term Loan Facility, and the SMR Notes, partially offset by the write-off of unamortized step-up related to the fair value step-up of EID's debt.
 Adjustments directly attributable to the separations and distributions of Corteva, Inc. include the following: removal of Telone[®] Soil Fumigant business ("Telone[®]") results (as Telone[®] did not transfer to Corteva as part of the part when the part we there the there the there the there the there there the there there the there there the there the there the there the there there there the there there the there there the there there the there there there the there there the there there there there there the there there there there the there there the there there there there there there

Adjustments directly attributable to the separations and distributions of Corteva, Inc. include the following: removal of Telone® Soil Furnigant business ("Telone®)" results (as Telone® did not transfer to Corteva as part of the common control combination of DAS); impact from the distribution agreement entered into between Corteva and Dow that allows for Corteva to become the exclusive distributor of Telone® products for Dow; elimination of one-time transaction costs directly attributable to the Corteva Distribution; the impact of certain manufacturing, leasing and supply agreements entered into in connection with the Corteva Distribution; and the related tax impacts of these items.

16 10 Corteva, Inc. Article 11 Pro Forma Combined Statement of Operations (Dollars in millions, except per share amounts)

					onths Ended er 31, 2019				
				Adju	stments				
	As Re	ported Corteva	 Merger ¹	Debt F	etirement ²	Separa	ations Related ³	Pro F	orma Corteva
Net sales	\$	13,846	\$ _	\$		\$	-	\$	13,846
Cost of goods sold		8,575	(205)		—		16		8,386
Research and development expense		1,147	—		—		—		1,147
Selling, general and administrative expenses		3,065	—		—		3		3,068
Amortization of intangibles		475	—		—		—		475
Restructuring and asset related charges - net		222	_		—		_		222
Integration and separation costs		744	_		_		(112)		632
Other income - net		215	_		—		_		215
Loss on early extinguishment of debt		13	_		_		_		13
Interest expense		136	_		(45)		_		91
(Loss) income from continuing operations before income taxes		(316)	 205		45		93		27
(Benefit from) provision for income taxes on continuing operations		(46)	36		10		1		1
(Loss) income from continuing operations after income taxes		(270)	 169		35		92		26
Net income from continuing operations attributable to noncontrolling interests		13	 		_		—		13
Net (loss) income from continuing operations attributable to Corteva	\$	(283)	\$ 169	\$	35	\$	92	\$	13
Basic (loss) earnings per share of common stock from continuing operations	\$	(0.38)						\$	0.02
Diluted (loss) earnings per share of common stock from continuing operations	\$	(0.38)						\$	0.02
Average number of shares outstanding used in earnings per share (EPS) calculation (in millions)									
Basic		749.5							749.5
Diluted		749.5							749.5

1. Related to the amortization of EID's agriculture business' inventory step-up recognized in connection with the Merger, as the incremental amortization is directly attributable to the Merger and will not have a continuing impact. 2. 3.

Represents removal of interest expense related to the debt redemptions/repayments. Adjustments directly attributable to the separations and distributions of Corteva, Inc. include the following: removal of Telone[®] Soil Fumigant business ("Telone[®]") results (as Telone[®] did not transfer to Corteva as part of the common control combination of DAS); impact from the distribution agreement entered into between Corteva and Dow that allows for Corteva to become the exclusive distributor of Telone[®] products for Dow; elimination of one-time transaction costs directly attributable to the Corteva Distribution; the impact of certain manufacturing, leasing and supply agreements entered into in connection with the Corteva Distribution; and the related tax impacts of these items.

17 1/ Corteva, Inc. Article 11 Pro Forma Combined Statement of Operations (Dollars in millions, except per share amounts)

						e Months Ended ember 31, 2018			
						Adjustments			
	As	Reported Corteva		Merger ¹	De	bt Retirement ²	Sepa	rations Related ³	Pro Forma Corteva
Net sales	\$	14,287	\$	_	\$	-	\$	-	\$ 14,287
Cost of goods sold		9,948		(1,554)		_		55	8,449
Research and development expense		1,355		-		—		(3)	1,352
Selling, general and administrative expenses		3,041		—		—		1	3,042
Amortization of intangibles		391		—		—		—	391
Restructuring and asset related charges - net		694		—		—		—	694
Integration and separation costs		992		—		—		(421)	571
Goodwill impairment charge		4,503		_		—		_	4,503
Other income - net		249		_		—		—	249
Loss on early extinguishment of debt		81		_		(81)		—	_
Interest expense		337		—		(261)		—	76
Loss from continuing operations before income taxes		(6,806)	_	1,554		342		368	(4,542)
(Benefit from) provision for income taxes on continuing operations		(31)		295		78		53	395
Loss from continuing operations after income taxes		(6,775)		1,259		264		315	(4,937)
Net income from continuing operations attributable to noncontrolling interests		29				_		_	 29
Net loss from continuing operations attributable to Corteva	\$	(6,804)	\$	1,259	\$	264	\$	315	\$ (4,966)
Basic loss per share of common stock from continuing operations	\$	(9.08)							\$ (6.63)
Diluted loss per share of common stock from continuing operations	\$	(9.08)							\$ (6.63)
Average number of shares outstanding used in earnings per share (EPS) calculation (in millions):									
Basic		749.4							749.4
Diluted		749.4							749.4

Related to the amortization of EID's agriculture business' inventory step-up recognized in connection with the Merger, as the incremental amortization is directly attributable to the Merger and will not have a continuing impact. 1. 2.

Represents removal of interest expense related to the debt redemptions/repayments and the removal of loss on extinguishment of debt related to the difference between the redemption price and the material material and travel of loss on extinguishment of debt related to the difference between the redemption price and the pravalue of the Make Whole Notes, the Term Loan Facility, and the SMR Notes, partially offset by the write-off of unamortized step-up related to the fair value step-up of EID's debt. Adjustments directly attributable to the separations and distributions of Corteva, Inc. include the following: removal of Telone[®] Soil Fumigant business ("Telone[®]") results (as Telone[®] did not transfer to Corteva as part of the common control combination of DAS); impact from the distribution; the impact of certain manufacturing, leasing and supply agreements entered into in connection with the Corteva Distribution; and the related tax impacts of the corteva and Dow that allows for Corteva to become the exclusive distribution; and the related tax impacts of the corteva and supply agreements entered into in connection with the Corteva Distribution; and the related tax impacts of the corteva interest entered into in connection with the Corteva Distribution; and the related tax impacts of the corteva and provide the corteva and prov 3. these items.



DRAFT 4Q/FY 2019 Earnings Conference Call

January 30, 2020

Safe Harbor Regarding Forward-Looking Statements

Forward-Looking Statements

This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securit Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may b identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates" or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's strategy for growth, product development, regulatory approval, market position, anticipated benefits of recent acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures, and financial results, as well as expected benefits from, the separation of Corteva from DuPont, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva's control. While the list of factors presented below is considered representative, no such list should be considered to a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements and other estimates Consequences of material differences in results as compared with those anticipated in the forward-looking statements and other estimates could include, among other things, business disruption operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva's business, results of operations and financial condition Some of the important factors that could cause Corteva's actual results to differ materially from those projected in any such forward-looking statements include: (i) effect of competition and consolida in Corteva's industry; (ii) failure to successfully develop and commercialize Corteva's pipeline; (iii) failure to obtain or maintain the necessary regulatory approvals for some Corteva's products; (iv) fa to enforce Corteva's intellectual property rights or defend against intellectual property claims asserted by others; (v) effect of competition from manufacturers of generic products; (vi) impact of Corteva is intellectual property rights or defend against intellectual property claims asserted by others; (v) effect of competition from manufacturers of generic products; (vi) impact of Corteva is intellectual property rights or defend against intellectual property claims asserted by others; (v) effect of competition from manufacturers of generic products; (vi) impact of Corteva is intellectual property rights or defend against intellectual property claims asserted by others; (v) effect of competition from manufacturers of generic products; (vi) impact of Corteva is intellectual property rights asserted by others; (vi) effect of competition from manufacturers of generic products; (vi) impact of Corteva is intellectual property rights asserted by others; (vi) effect of competition from manufacturers of generic products; (vi) impact of Corteva is intellectual property rights asserted by others; (vi) effect of competition from manufacturers of generic products; (vi) impact of Corteva is intellectual property rights asserted by others; (vi) effect of competition from manufacturers of generic products; (vi) impact of Corteva is intellectual property rights asserted by others; (vi) effect of competition from manufacturers of generic products; (vi) impact of Corteva is intellectual property rights asserted by others; (vi) effect of competition from manufacturers of generic products; (vi) effect of competition from manufacturers of generic products; (vi) effect of competition from manufacturers of generic products; (vi) effect of competition from manufacturers of generic products; (vi) effect of competition from manufacturers of generic products; (vi) effect of competition from manufacturers of generic products; (vi) effect of competition from manufacturers of generic products; (vi) effect of competition from manufacturers dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (vii) costs of complying with evolving regulatory requirements and the effect of actual or alle violations of environmental laws or permit requirements; (viii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products; (ix) effect of changes in agricultural and related policies of governments and international organizations; (x) effect of disruptions to Corteva's supply chain, information technolog network systems; (xi) competitor's establishment of an intermediary platform for distribution of Corteva's products; (xii) effect of volatility in Corteva's input costs; (xiii) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xiv) failure of Corteva's customers to pay their debts to Corteva, including customer financing programs; (xv) failure to reali the anticipated benefits of the internal reorganizations taken by DowDuPont in connection with the spin-off of Corteva; (xvi) failure to benefit from significant cost synergies and risks related to the indemnification obligations of legacy DuPont liabilities in connection with the separation of Corteva; (xvii) increases in pension and other post-employment benefit plan funding obligations; (xviii) effective of the separation o compliance with environmental laws and requirements and adverse judgments on litigation; (xix) risks related to Corteva's global operations; (xx) effect of climate change and unpredictable seasona weather factors; (xxi) effect of counterfeit products; (xxii) failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions; (xxiii) risks related to non-cash charges from the impairment of goodwill and intangible assets; and (xxiv) other risks related to Corteva's Separation from DowDuPont.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement or other estimate, except as required by applicable law. A detailed discussion of some of the signil risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the "Risk Factors" section of Exhibit 99.1 of Amendment No. 4 to Corteva's Registration Statement on Form 10 and Corteva's Quarterly Report on Form 10-Q for the period ended September 30, 2019, as modified by subsequent reports on For 10-Q and 10-K and Current Reports on Form 8-K.



A Reminder About Non-GAAP Financial Measures and Pro Forma Financial Information

Corteva Unaudited Pro Forma Financial Information

In order to provide the most meaningful comparison of results of operations, supplemental unaudited pro forma financial information for the first quarter of 2019 and prior has been included in this presentation. This preser presents the pro forma results of Corteva, after giving effect to events that are (1) directly attributable to the merger of DuPont and Dow, debt retirement transactions related to paying off or retiring portions of Historical Du existing debt liabilities, and the separation and distribution to DowDuPont stockholders of all the outstanding shares of Corteva common stock; (2) factually supportable and (3) with respect to the pro forma statements of in expected to have a continuing impact on the consolidated results. Refer to Corteva's Form 10 registration statement filed on May 6, 2019, which can be found on the investors section of the Corteva website, for further del above transactions. The pro forma financial statements were prepared in accordance with Article 11 of Regulation S-X, and are presented for informational purposes only, and do not purport to represent what the results c would have been had the above actually occurred on the dates indicated, nor do they purport to project the results of operations for any future period or as of any future date.

Regulation G (Non-GAAP Financial Measures)

This earnings release includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures include organic sales, operating EBITDA, pro forma operating EBITDA margin, operating earnings per share, pro forma operating earnings per share, base tax rate, pro forma base tax rate, and adjusted return on invested capital. Management believes the GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing oper of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing oper of the Company and a more useful comparison of year over year results. These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measure performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided in the prepared and provide matures to their most directly attributable U.S. GAAP measures are being reconciled to a pro forma GAAP finance prepared and presented in accordance with Article 11 of Regulations 5/x. Reconciliations for these non-GAAP measures to their most directly attributable U.S. GAAP measure are provided on slides 21 - 28 of this present


Corteva is not able to reconcile its forward-looking non-GAAP financial measures to their most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the company's such as Significant Items, without unreasonable effort. For Significant Items reported in the periods presented, refer to page 8 of the Financial Statement Schedules. Beginning January 1, 2020, the company will present a prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization expresses the noncash charge associated with the recognition of upfront payments made to Monsanto in connection wi Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® Roundup Ready 2 Xtend® herbicide tolerance traits. During the five-year ramp-up period of Enlist E's expected to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. During the five-year ramp-up period of Enlist E's expected to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform after completion of the ramp-up.


Organic sales is defined as price and volume and excludes currency and portfolio impacts. Operating EBITDA is defined as earnings (i.e., income from continuing operations before income taxes) before interest, deprecial amortization, non-operating benefits, net and foreign exchange gains (losses), excluding the impact of significant items (including goodwill impairment charges). Non-operating benefits, net consists of non-operating pensis post-employment benefit (OPEB) credits, tax indemnification adjustments, environmental remediation and legal costs associated with legacy businesses and sites of Historical DuPont. Tax indemnification adjustments, environmental remediation and legal costs associated with legacy businesses and sites of Historical DuPont. Tax indemnification adjustments relic charges in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. C EBITDA margin is defined as Operating EBITDA as a percentage of net sales. Operating earnings per share are defined as "Earnings per common share from continuing operations - diluted" excluding the after-tax impact of non-operating benefits, net, and the after-tax impact of amortization of the Company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute i generation. Amortization of intangible assets is excluding the impacts of foreign exchange gains (losses), non-operating benefits, net, amortization of intangibles as of the Separation for DowDuPont, and significant items (including goodwill impairment charges). Adjusted return on invested capital is defined as net income from continuing operations attributable to Corteva excluding the after-tax impact of amortization expense associated with intangible assets in a soft. The DowDuPont, the after-tax impact of amortization expense associated with intangibl



Full Year 2019 Highlights








Highlights Outside of North America, net sale

Organic Growth⁽¹⁾ Outside of North America

Organic sales, Operating EBITDA and Operating EBITDA Margin are non-GAAP measures. See slide 3 for further discussion.
 First quarter 2019 and prior year information is on a pro forma basis and was determined in accordance with Article 11 of Regulation S-X.
 Rest of World is defined as Europe, Middle East and Article (EMEA), Lain America and Asia Pacific and excludes North America (U.S. and Canada).
 SARD is defined as Selling, General & Administrative and Research & Development expense combined.



Continued Focus on ROIC⁽¹⁾ to Ensure Capital Discipline



(1) Return on Invested Capital (ROIC) is not defined under U.S. generally accepted accounting principles. Therefore, ROIC should not be considered a substitute for other measures prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. The company's ROIC muddle as net income from continuing operations attributable to Corteva excluding the after-tax impact of significant items (including good/will impairment charges), the after-tax impact of non-operating benefits, net, the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from Do

Progress on Five Priorities for Shareholder Value Creation

2019 Highlights

02 05 01 03 04 **Drive disciplined Develop innovative Deliver above-**Instill a strong Attain best-in-class culture capital allocation solutions cost structure market growth Realized merger cost U.S. Pioneer brar Launched Enlist E3™ Launched new pure Authorized capital synergies of \$350 share gain⁽¹⁾ soybeans and Qrome® play agriculture expansion to support million for the full year corn company with the Spinosyns growth Insecticides globa Corteva brand, Authorized ERP growth Received China import Authorized \$1 billion values, and purpose project targeted at approval for Conkesta share repurchase Launched new eliminating inherited soybean trait Initiated companyprogram global retail branc costs wide effort focused Brevant □ Ramped Arylex[™] Returned on instilling an owner Reduced R&D costs herbicide, Isoclast™ approximately \$220 Restructured U.S mindset to drive 15 percent insecticide, and million to regional seed sustainable Zorvec[™] fungicide shareholders through Committed to holding brands productivity focus dividends and share Corporate costs at Accelerated launch of buybacks over 7 less than 1 percent of Enlist E3^{™(2)} in North months since spin net sales America Based on current reported USDA acreage for 2019 Enlist E3[™] soybeans are jointly developed by Dow AgroSciences and MS Technologies[™]


Full Year 2019 Regional Highlights



2019 Customer Event Highlights




Full Year 2019 Segment Performance Highlights



Seed								
(\$ in millions)	2018 ⁽¹⁾	2019 ⁽¹⁾						
Net Sales	\$7,842	\$7,590						
Operating EBITDA	\$1,139	\$1,040						
Operating EBITDA Margin	14.5%	13.7%						





First quarter 2019 and prior year information is on a pro forma basis and was determined in accordance with Article 11 of Regulation S-X.
 Production costs are net of synergies realized in the period.
 Non-Production Costs includes costs such as selling, leveraged function costs and product development, net of synergies realized in the period
 Other includes gain on divestitures



2019 Product Highlights

Ins	ecticides			Corn Seed		Soyb	bean Seed	ed	
Insecticide Net Sales	FY 2018	FY 2019	Corn Net Sales	FY 2018	FY 2019	Soybean Net Sales	FY 2018	FY 20	
Net Sales (\$MM)	\$1,506	\$1,652	Net Sales (\$MM)	\$5,180	\$5,111	Net Sales (\$MM)	\$1,494	\$1,	
Spir	nosyns						Enlist E3 SOYBEANS		
 Expansion for Mid with full productiv Capacity expansion pre-merger levels address global mainsecticides to have 	vity expected i on will essent at full utilizati arket growth i	in 2024 tially double tion to in	in U.S. for trip Expanded ava products acro	acres as address le stack of defen ilability of high-y ss U.S. corn belt -20% of lineup	sive traits rield potential	 Accelerating ramp portfolio Estimated coverag America acres⁽¹⁾ in of >10% 	ge of ~20% of t	total No	
Differentiated tech formulation and m				mance and high y rmers using Qro e yield advantage		 ~30% of market report of the second se			
 Corteva holds ~10 insecticide market Contributed ~40% 	t			ort authorization as delayed by 3 y		Long-term value cr to proprietary trait beginning in 2023	reation by shi with margin e	ft in por	
organic sales grov America in 2019			Low single dig revenue growt	git mix benefit co th in 2020	ntributing to	Overall, Enlist [™] sy million of sales in	ystem contrib	uted >\$2	

4Q 2019 Highlights


(\$'s in millions, except EPS)	4Q 2018 ⁽¹⁾	4Q 2019	Change
Net Sales	\$2,815	\$2,983	6%
GAAP Loss from Continuing Operations After Income Taxes	\$(746)	\$(42)	94%
Operating EBITDA ⁽²⁾	\$50	\$224	348%
Operating EBITDA Margin ⁽²⁾	1.8%	7.5%	~570 bps
GAAP EPS from Continuing Operations	\$(1.00)	\$(0.06)	94%
Operating EPS ⁽²⁾	\$(0.10)	\$0.07	170%



019 and prior year information is on a pro-forma basis and was determined in accordance with Article 11 of Regulation S-X. Operating EBITDA, Operating EBITDA margin and Operating earnings per share are non-GAAP measures. See slide 3 for further discussi interview.



Full Year 2019 Operating EPS⁽¹⁾ Variance





Full Year 2020 Guidance



Guidance aligned with mid-term targets and risk-adjusted for market uncertainties

(1) Operating EBITDA, Operating EBITDA Margin and Operating EPS are non-GAAP measures. See slide 3 for further discussion. (2) First quarter 2019 and prior year information is on a pro forma basis and was determined in accordance with Article 11 of Regulation S-X.



2020 Key Assumptions

Sales Growth

Organic Growth⁽¹⁾ +4 – 5%

- U.S. planted area: +11 million acres (1/3 corn, 2/3 soybeans)
- Low single digit realized pricing on corn globally
 - ~\$50 million North America soybean price headwind
- Crop Protection new product sales growth ~\$250 million

Currency flat versus prior year

Product divestitures

 2019 net sales for divested product ~\$(70) million on an annualized basis

(1) Organic sales is a non-GAAP measures. See slide 3 for further discussion.



Synergies / Costs

Synergies / Productivity

- \$200 million in merger-related synergies – COGS improvement
- Productivity actions ~\$30 million
- Combined SG&A and R&D as a percent of sales down ~20 bps
- 2020 Corporate costs <1% of sales

Investment / Input Costs

- ~\$150 million of COGS related headwinds, including higher royalty costs due to ramp of Enlist[™] E3
- ~\$50 million in costs associated with ERP implementation – on track to begin deliver savings by 2022

Other Financial

Commitment to Return C to Shareholders

- Dividends: ~\$400 million
- Continued execution against repurchase program with excash

Pension

- Funded level ~80% (GAAP)
- ~\$300 million in Pension an OPEB payments

Capital Expenditures

\$500 - \$600 million



Full Year 2019 Regional Net Sales Highlights – Crop Protection



		FY 2018	FY 2019
et Sales (\$	SMM)	\$2,438	\$2,205
Volume	Price	Currency	Portfolio
(6)%	(3)%	- %	(1)%
		Reported (ams
MEA		Reported 0	Organic ⁽¹⁾
MEA			Organic ⁽¹⁾
	6MM)	Flat 1	Drganic ⁽¹⁾
MEA let Sales (\$ /olume	§MM) Price	Flat 1	Drganic ⁽¹⁾ 7% FY 2019 \$1,362
et Sales (\$	Selected S	Flat 1 FY 2018 \$1,357	Drganic ⁽¹⁾ 7% FY 2019 \$1,362

Latin America		orted Organio	
		FY 2018	FY 2
Net Sales (Net Sales (\$MM)		\$1
Volume	Price	Currency	Por
7%	1%	(5)%	13
Isoclast [™] fungicide	^M insectio	r new produc ide and Vess ncy impact fro	arya™
Isoclast ^{TI} fungicide Unfavora Real Asia	^M insectic ble curre R	ide and Vess ncy impact fro	arya ^{Ti} om Br
Isoclast ^{TI} fungicide Unfavora Real	^M insectic ble curre R	ide and Vess	arya ^{Ti} om Br
Isoclast ^{TI} fungicide Unfavora Real Asia	^M insectic ble curre R	ide and Vess ncy impact fro eported Organ 1% 1 39	arya ^{Ti} om Br
Isoclast ^{TI} fungicide Unfavora Real Asia	Minsectic ble curre	ide and Vess ncy impact fro eported Organ 1% 1 39	arya ^{TI} om Br ic ⁽¹⁾
Isoclast [™] fungicide Unfavora Real Asia Pacific	Minsectic ble curre	ide and Vess ncy impact fro eported Organ 1% 139 FY 2018	arya ^{TI} om Br ic ⁽¹⁾ 6 FY 20

and retailer interface underpinning performance

(1) Organic sales growth is a non-GAAP measures. See slide 3 for further discussion. (2) Rest of World is defined as Europe, Middle East and Africa (EMEA), Latin America and Asia Pacific and excludes North America (U.S. and Canada). (3) North America is defined as U.S. and Canada.

Full Year 2019 Regional Net Sales Highlights - Seed



North America) (3)		Drganic ⁽¹⁾	Latin America		- p	Organi	
		FY 2018	4Q 2019			FY 201	18	FY :
Net Sales (\$MM)	\$4,974	\$4,724	Net Sales	(\$MM)	\$1,1	02	\$1
Volume	Price	Currency	Portfolio	Volume	Price	Curr	rency	Po
(3)%	(2)%	- %	- %	(1)%	8%	(4)%	
		sures in soyl wnward pricir Reported \$2%	ng	growth Early stavolumes	R	eported	4Q18 Organi 1 4%	c ⁽¹⁾
		FY 2018	FY 2019			FY 2018	3	FY 20
Net Sales (\$MM)	\$1,408	\$1,378	Net Sales (S	\$MM)	\$358		\$3
Volume	Price	Currency	Portfolio	Volume	Price	Curre	ncy	Port
5%	1%	(8)%	- %	2%	2%	(4)%	%	-
Direct N	Nodel dro	Eastern Euro ve volume gr	owth	Volume	and price	growth	in cor	n in (

(1) Organic sales growth is a non-GAAP measures. See slide 3 for further discussion.
(2) Rest of World is defined as Europe, Middle East and Africa (EMEA), Latin America and Asia Pacific and excludes North America (U.S. and Canada).
(3) North America is defined as U.S. and Canada.

CORTEVA"

4Q 2019 Segment Performance Highlights

Crop Protection Performance Highlights							
(\$'s in millions)	4Q 2018 ⁽¹⁾	4Q 2019	 Strong demand in North America led by ramp up of Enli herbicide and in Latin America for insecticides, partially 				
Net Sales	\$1,689	\$1,740	by currency headwinds, customer program discounts ar portfolio changes				
Operating EBITDA	\$169	\$277	 Operating EBITDA improvement led by cost synergies, 				
Operating EBITDA Margin	10.0%	15.9%	on divestitures and improved volumes on new products partially offset by increased selling costs. Gains on divestitures in the quarter were approximately \$70 millic				

	5	Seed Performa	ance Highlights
(\$'s in millions)	4Q 2018 ⁽¹⁾	4Q 2019	 Stronger sales due to favorable mix in Latin America on DeverCase Ultra® construction and increased delivering
Net Sales	\$1,126	\$1,243	PowerCore Ultra® penetration and increased deliveries multi-channel brands in North America, partially offset b
Operating EBITDA	\$(87)	\$(26)	 Unfavorable currency Operating EBITDA improvement on stronger pricing an
Operating EBITDA Margin	(7.7)%	(2.1)%	synergies and ongoing productivity, partially offset by hi input costs

(1) First quarter 2019 and prior year information is on a pro forma basis and was determined in accordance with Article 11 of Regulation S-X

FY20 Modeling Guidance - Operating Earnings Per Share⁽¹⁾

(\$ in millions, except where noted)	Guidance	Commentary		
Depreciation	(575 – 625)			
Interest Income	25 – 30			
Interest Expense	(90 – 110)	Primarily represents cost of short-term borrowings to fund working capital		
Base Tax Rate ⁽¹⁾	19% - 21%			
Exchange Losses – net, after tax	(60 – 80)	Represents cost of balance sheet hedging program, net of tax		
Net Income – Non- controlling interest	(20 – 30)			
Diluted Shares	~750 - 752			
Operating Earnings Per Share ⁽¹⁾	~\$1.45 – 1.55	+5% vPY using the midpoint		

(1) Base tax rate and operating earnings per share are non-GAAP measures. Corteva does not provide a reconciliation of forward-looking non-GAAP measures. See slide 3 for further discussion



Continued Focus on ROIC to Ensure Capital Discipline

Return on Invested Capital (ROIC) Calculation ⁽³⁾	2019 ROIC			
Numerator	19.8%			
Operating Earnings ⁽¹⁾	(\$ in millions)			
(-) Interest Expense, pre-tax	Numerator	FY 20		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Net income (loss) from continuing operations attributable to Corteva	s		
(-) (Interest Income, pre-tax)	Less: Non-operating benefits - net, after tax			
(-) Provision on interest income/(expense), net	Less: Amortization of intangibles (as of Separation), after tax Less: Significant items charge, after tax			
	Operating Earnings	\$ 1		
Adjusted NOPAT	Less: Interest Expense, pre-tax Less: Interest Income, pre-tax			
	Less: Benefit from income taxes on interest income and			
	Adjusted NOPAT	\$ 1		
Denominator (Four quarter avg.)	Denominator			
(+) Shareholder's Equity incl. NCI	Goodwill	1		
	Other Intangibles Total goodwill and other intangible assets (as of	1		
(+) Total debt	Separation)	\$ 21		
(-) Total goodwill and intangibles (existing as	Short term borrowings and finance lease obligations			
of Separation)	Long-term debt Total Debt	\$		
	Total Equity ⁽²⁾	\$ 2		
Adjusted Invested Capital	Total Debt plus Equity	\$ 27		
	Total Debt plus Equity, less goodwill and other intangible assets ("Adjusted Invested Capital")	\$ 5		

is adjusted and is defined as net come and the after-tax impact of it



Corteva Non-GAAP Calculation of Corteva Operating EBITDA

	Three	Months En	ded December 31,	Twelve Months Ended December 31,			
		2019	2018	2019		2018 Pro Forma	
In millions	As I	eported	Pro Forma	Pro Forma			
(Loss) income from continuing operations, net of tax (GAAP) ¹	\$	(42)	\$ (746)	\$ 2	5 \$	(4,937	
(Benefit for) provision for income taxes		(145)	201		1	395	
(Loss) income from continuing operations before income taxes	\$	(187)	\$ (545)	\$ 2	7 \$	(4,542)	
+ Depreciation and Amortization		289	242	1,00	0	909	
- Interest income		(13)	(23)	(5	9)	(86	
+ Interest expense		24	25	9	1	76	
+ / - Exchange losses (gains), net		29	(63)	6	5	77	
+ / - Non-operating benefits, net		(23)	(56)	(12	9)	(211	
+ Goodwill impairment charge		-	-	10 g	-	4,503	
+ Significant items charge		105	470	99	1	1,346	
Corteva Operating EBITDA (Non-GAAP) ²	\$	224	\$ 50	\$ 1,98	7 \$	2,072	

1. Pro forma (loss) income from continuing operations, net of tax, has been prepared in accordance with Article 11 of Regulation S-X and is considered the most directly comparable GAAP measure to Pro Forma Operating EBITDA.

2. Corteva Operating EBITDA is defined as earnings (i.e., income from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs) - net and foreign exchange gains (losses), excluding the impact of significant items (including goodwill impairment charges). Non-operating benefits (costs) - net consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, environmental remediation and legal costs associated with Historical DuPont businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.



	2019	2	018		2010		
6			010	2019		2018	
\$	1,243 1,740	\$	1,126 1,689	\$	7,590 6,256	\$	7,84 6,44
\$	2,983	\$	2,815	\$	13,846	\$	14,28
As R	eported	Pro Forma		Pro Forma		Pro Forma	
\$	(26)	\$	(87)	\$	1,040	\$	1,1
	12743				27.5.5.6		1,0
					1	1	(1
\$	224	\$	50	\$	1,987	\$	2,0
	Three 2 As R	\$ 2,983 Three Months En- 2019 As Reported \$ (26) 277 (27)	\$ 2,983 \$ Three Months Ended Dece 2019 22 As Reported Pro I \$ (26) \$ 277 (27)	S 2,983 S 2,815 Three Months Ended December 31, 2019 2019 2018 As Reported Pro Forma \$ (26) \$ 277 169 (27) (32)	S 2,983 S 2.815 S Three Months Ended December 31, 2019 Twelw 2018 2019 Twelw 2019 Pro S (26) S (27) S Pro S (26) S (27) S Pro S (27) S Pro S (26) S (27) S Pro S (27) S Pro S (26) S (27) S Pro S (27) S (27) (32) Pro Pro <th< th=""><th>\$ 2,983 \$ 2,815 \$ 13,846 Three Months Ended December 31, 2019 Twelve Months Ended December 31, 2019 As Reported Pro Forma Pro Forma \$ (26) \$ (87) \$ 1,040 277 169 1,066 (27) (32) (119)</th><th>\$ 2,983 \$ 2,815 \$ 13,846 \$ Three Months Ended December 31, Twelve Months Ended December 31, 2019 2018 2019 2019 As Reported Pro Forma Pro Forma Pro \$ (26) \$ (87) \$ 1,040 \$ 277 169 1,066 (27) (32) (119)</th></th<>	\$ 2,983 \$ 2,815 \$ 13,846 Three Months Ended December 31, 2019 Twelve Months Ended December 31, 2019 As Reported Pro Forma Pro Forma \$ (26) \$ (87) \$ 1,040 277 169 1,066 (27) (32) (119)	\$ 2,983 \$ 2,815 \$ 13,846 \$ Three Months Ended December 31, Twelve Months Ended December 31, 2019 2018 2019 2019 As Reported Pro Forma Pro Forma Pro \$ (26) \$ (87) \$ 1,040 \$ 277 169 1,066 (27) (32) (119)

	Three Months End	ed December 31,	Twelve Months Ended December 31,			
	2019	2018	2019	2018		
	As Reported	Pro Forma	Pro Forma	Pro Forma		
Seed	-2.1%	-7.7%	13.7%	14.5%		
Crop Protection	15.9%	10.0%	17.0%	16.7%		
Total Operating EBITDA margin (Non-GAAP) ^{2,3}	7.5%	1,8%	14.4%	14.5%		

Operating EBITDA margin is Operating EBITDA as a percentage of net sales.
 Operating EBITDA margin %s for Corporate are not presented separately above as they are not meaningful; however, the results are included in the Total margin %s above.



	Three Months End	led December 31,	Twelve Months Ended December 3			
	2019	2018	2019	2018		
In millions	As Reported	Pro Forma	Pro Forma	Pro Forma		
Seed						
Loss on deconsolidation	14 C	(53)	2.2	(53		
Loss on divestiture		(2)	(24)	(3		
Gain on sale of assets	-	2	-	24		
Restructuring and asset-related charges - net	(90)	(95)	(213)	(368		
Inventory amortization	075).		(67)	1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 -		
Total Seed	(90)	(150)	(304)	(399		
Crop Protection						
Restructuring and asset-related benefits (charges) - net	1	(16)	(23)	(5)		
Total Crop Protection	1	(16)	(23)	(58		
Corporate						
Integration and separation costs	(50)	(187)	(632)	(57)		
Loss on debt extinguishment	-	-	(13)	1 C		
Restructuring and asset-related charges - net	34	(117)	14	(268		
Argentina devaluation	(2)		(33)	-		
Income tax items ¹	12	2 .	22	(50		
Total Corporate	(16)	(304)	(664)	(889		
Fotal significant items by segment (Pretax)	(105)	(470)	(991)	(1,340		
Total tax impact of significant items	83	107	135	239		
Tax only significant items	34	(274)	72	(34		
Fotal significant items benefit (charge), net of tax	\$ 12	\$ (637)	\$ (784)	\$ (1,454		



Corteva Segment Information - Price, Volume Ci	urrency Analysis												
Region					15								
	-	Q4 2019 v	s. Q4 2018			Percent Char	ge Due To:						
	Net Sales C	hange (GAAP)	Organic Chan	ge (Non-GAAP)	Local Price &			Portfolio /					
	\$ (millions)	%	\$ (millions)	%	Product Mix	Volume	Currency	Other					
North America	\$ 151	15%	\$ 156	16%	2%	14%	%	-1					
EMEA	18	5%	25	7%	4%	3%	-2%).					
Asia Pacific	(27)	-7%	(23)	-6%	-2%	-4%	1%	-2					
Latin America	26	2%	95	8%	4%	4%	-6%						
Rest of World	17	1%	97	5%	3%	2%	-4%						
Total	S 168	6%	\$ 253	9%	3%	6%	-3%						
		hange (GAAP)		ge (Non-GAAP)	Percent Change Due								Portfolio /
	S (millions)	nange (GAAP) %	S (millions)	ge (Non-GAAP) %	Local Price & Product Mix	Volume	Currency	Portfolio / Other					
North America	\$ 102	27%		26%	10%	16%	_%	1					
EMEA	(8)	-4%	(7)	-3%	-1%	-2%	-1%						
Asia Pacific	(1)	-1%	· · · · · · · · · · · · · · · · · · ·	-4%	-2%	-2%	3%	_					
Latin America	24	5%	53	11%	12%	-1%	-6%	_					
Rest of World	15	2%	42	6%	7%	-1%	-4%						
Total	\$ 117	10%	\$ 142	13%	8%	5%	-3%						
Crop Protection			s. Q4 2018			Percent Char	ge Due To:						
	Net Sales C	hange (GAAP)	Organic Chan	ge (Non-GAAP)	Local Price &			Portfolio /					
	\$ (millions)	%	\$ (millions)	%	Product Mix	Volume	Currency	Other					
North America	\$ 49	8%	S 56	9%	-4%	13%	_%	-1					
EMEA	26	13%	32	16%	9%	7%	-3%	-					
Asia Pacific	(26)	-9%	(19)	-7%	-2%	-5%	1%	-3					
Latin America	2	_%	42	7%	-1%	8%	-7%	-					
				50/	1%	4%	-4%	-1					
Rest of World	2	-%	55 \$ 111	5%	-1%	470	-470	-1					

	Twelve Mon	ths Ended December	31, 2019 vs.	Twelve Months Ended I	December 31, 2018		Percent Change Due To:			
		ales Change (GAAP		Organic Change		Local Price &			Portfolio /	
North America	\$ (millions)	(483)	-7% \$	\$ (millions) (448)	%	Product Mix -2%	Volume -4%	Currency -1%	Other	
EMEA	*	(485)	-1%	189	-076	2%	5%	-8%		
Asia Pacific		(5)	04	43	3%	2%	1%	-3%		
Latin America		72	3%	208	8%	4%	4%	-5%		
Rest of World		42	1%	440	7%	3%	4%	-6%	-	
Total	s	(441)	-3% 5		_%	%	-%	-3%		
	\$ (millions)			\$ (millions)	%	Product Mix	Volume	Currency	Other	
		Net Sales Change (GAAP)		Organic Change (Non-GAAP)		Local Price &		Portfolio /		
North America	S	(250)	-5% \$		-5%	-2%	-3%	_%	-	
EMEA	~	(30)	-2%	85	6%	1%	5%	-8%		
Asia Pacific			%	14	4%	2%	2%	-4%		
Latin America		28	3%	82	7%	8%	-1%	-4%		
Rest of World		(2)	%	181	6%	4%	2%	-6%		
Total	\$	(252)	-3% 5	\$ (56)	-1%	%	-1%	-2%		
Crop Protection	- An	101 10085	100	or and the			~~~			
Crop Froiection	Twelve Mon	hs Ended December	31, 2019 vs.	Twelve Months Ended I	December 31, 2018	Percent Change Due To:				
		ales Change (GAAP)	Organic Change	(Non-GAAP)	Local Price &	1		Portfolio /	
	Net S	ares change (GALA		\$ (millions)	%	Product Mix	Volume	Currency	Other	
	Net S \$ (millions)			151 A 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		102312	-6%	0/		
			-10% \$		-9%	-3%	-070			
	\$ (millions)	%			-9% 7%	-3% 2%	-5%	-7%	1	
North America	\$ (millions)	(233)	-10% \$	\$ (211)		0.000	121167	-3%	-	
North America EMEA	\$ (millions)	(233) 5	-10% \$ —%	6 (211) 104	7%	2%	121167	-3% -5%	8	
North America EMEA Asia Pacific	\$ (millions)	(233) 5 (5)	-10% 5 —% -1%	5 (211) 104 29	7% 3%	2% 3%	5% —%	-3%	8	

Corteva Non-GAAP Calculation of Corteva Operating EPS								
-			Th	ree Months En	ded De	cember 31,		
	2019 \$ (millions)		2018 S (millions)		2019 EPS (diluted)		2018 EPS (diluted)	
	As Repo	orted	_8	Pro Forma	As .	Reported	P	o Forma
Net loss from continuing operations attributable to Corteva (GAAP)	\$	(45)	\$	(752)	\$	(0.06)	s	(1.00)
Less: Non-operating benefits - net, after tax		16		44		0.02		0.06
Less: Amortization of intangibles (existing as of Separation), after tax		(126)		(86)		(0.17)		(0.11)
Less: Significant items benefit (charge), after tax		12		(637)	-	0.02		(0.85)
Operating Earnings (Loss) (Non-GAAP) ¹	s	53	\$	(73)	\$	0.07	s	(0.10

	Twelve Months Ended December 31,										
		2019		2018	2	2019		2018			
	\$ (m	illions)	\$ (millions)	EPS	(diluted)	EPS	(diluted)			
	Pro	Forma	Pi	ro Forma	Pro	o Forma	Pro	Forma			
Net income (loss) from continuing operations attributable to Corteva (GAAP)	s	13	\$	(4,966)	s	0.02	s	(6.63			
Less: Non-operating benefits - net, after tax	~	100	011	165	363	0.13		0.22			
Less: Amortization of intangibles (existing as of Separation), after tax		(376)		(313)		(0.50)		(0.42			
Less: Goodwill impairment charge, after tax				(4,503)				(6.01			
Less: Significant items charge, after tax		(784)		(1,454)		(1.04)		(1.94			
Operating Earnings (Non-GAAP) ¹	S	1,073	\$	1,139	s	1.43	s	1.52			
Less: Interest Expense, pre-tax		(91)									
Less: Interest Income, pre-tax		59									
Less: Benefit from income taxes on interest income and expense, net		6									
Adjusted NOPAT (Non-GAAP) ²	\$	1,099									

1. Operating earnings is defined as net income from continuing operations attributable to Corteva excluding the after-tax impact of significant items (including goodwill impairment charges), non-operating benefits - net, and amortization of intangible assets (existing as of Separation). Although amortization of intangible assets (existing as of Separation) is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets

2. Adjusted NOPAT is defined as operating earnings excluding interest expense, interest income, and the income tax effects of interest expense and interest income.



	Three Mo	ths En	ded De	cember 31,	Twelve	Months En	ded De	cember 31.
	2019 2018		2019		2018			
	As Repor	ted	P)	o Forma	Pro F	orma	Pr	o Forma
Net (loss) income from continuing operations before income taxes (GAAP)	s	(187)	\$	(545)	s	27	\$	(4,542
Add: Significant items - charge		105		470		991		1,346
Goodwill impairment charge		- E -				880		4,50
Non-operating benefits - net		(23)		(56)		(129)		(21
Amortization of intangibles (existing as of Separation)		161		107		475		391
Less: Exchange (losses) gains, net		(29)		63		(66)		(77
Income (loss) from continuing operations before income taxes, significant items, goodwill impairment charges, non-operating benefits – net, amoritzation of intangibles (existing as of Separation), and exchange gains (losses), net (Non-GAAP)	s	85	\$	(87)	s	1,430	\$	1,564
Benefit from) provision for income taxes on continuing operations	2						120	1.2
(GAAP)	\$	(145)	\$	201	\$	1	\$	39:
Add: Tax benefits (expenses) on significant items charge		117		(167)		207		(10
Tax expenses on goodwill impairment charge				2 1992 (1		vian Vitaten		121
Tax expenses on non-operating benefits - net		(7)		(12)		(29)		(4
Tax benefits on amortization of intangibles (existing as of Separation)		35		21		99		7
Tax benefits (expenses) on exchange gains (losses), net	2	15		(78)		2		(6
Provision for (benefit from) income taxes on continuing operations before significant items, goodwill impairment charges, non- operating benefits - net, amortization of intangibles (existing as of Separation), and exchange (gains) losses, net (Non-GAAP)	s	15	s	(35)	s	280	\$	25
o opan and only and one and a games (conserved and (conserved a)	3	15	9	(33)	3	200	3	20
Effective income tax rate (GAAP)		77.5%		-36.9%		3.7%		-8.7
Significant items, goodwill impairment charge, non-operating benefits, and amortization of intangibles (existing as of Separation) effect	1	77.5%		-142.3%		16.7%		30.2
Fax rate from continuing operations before significant items, goodwill mpairment charge, non-operating benefits - net, and amortization of ntangibles (existing as of Separation)		0.0%		-179.2%		20.4%		21.5
Exchange gains (losses) effect		17.6%	-	219.4%		-0.8%		-5.2
Base income tax rate from continuing operations (Non-GAAP) ¹		17.6%		40.2%		19.6%		16.3

Corteva Non-GAAP Calculation of Adjusted Return on Invested Capital (ROIC)

Adjusted Invested Capital (in millions)						
	March 31, 2019	June 30, 2019	September 30, 2019	December 31, 2019	Trailing Twelve	
	Pro Forma	As Reported	As Reported	As Reported	Pro Form	
Goodwill	\$ 10,203	\$ 10,249	\$ 10,168	\$ 10,229	\$	
Other intangible assets	11,961	11,832	11,667	11,424		
Total goodwill and other intangible assets (existing as of Separation)	22,164	22,081	21,835	21,653		
Short term borrowings and finance lease obligations	\$ 2,716	\$ 2,058	\$ 3,604	\$ 7	\$	
Long-term debt	183	117	116	115		
Total Debt	2,899	2,175	3,720	122		
Total Equity ¹	25,145	26,067	25,261	24,555		
Total Debt plus Equity	28,044	28,242	28,981	24,677		
Total Debt plus Equity, less goodwill and other intangible assets (existing as of Separation) ("Adjusted Invested Capital")	\$ 5,880	\$ 6,161	s 7,146	\$ 3,024	s	
Adjusted NOPAT ²	e 1000					
Adjusted NOPAT Adjusted Invested Capital	\$ 1,099 \$ 5,553					
Adjusted Return on Invested Capital ³	19.8%					

1. The company has revised the balance of additional paid in capital as of 6/30/2019 in the amount of \$76 million to reflect the removal of an asset related to the Separation.

Adjusted NOPAT is defined as net income from continuing operations attributable to Corteva excluding the after-tax impact of significant items (including goodwill impairment charges), the after-tax impact of non-operating benefits, net, the after-tax impact of significant items (including goodwill impairment charges), the after-tax impact of non-operating benefits, net, the after-tax impact of interest expense associated with intangible assets existing as of Separation, the after-tax impact of interest income and the after-tax impact of interest expense divided by debt plus equity excluding goodwill and intangibles (existing as of Separation)
 Adjusted Return on Invested Capital ("ROIC") is defined as Adjusted NOPAT divided by debt plus equity excluding goodwill and intangibles (existing as of Separation).